Worldwide Healthcare (Ordinary Share) WWH

Sector Specialist: Biotechnology/Life Sciences

Register or Sign in to receive email alerts for items in your favourites whenever we write about them

Add to Virtual Portfolio | Print page

Estimated NAV

2251.00

Share Price

2069.56

Total Returns on £1000 over 

Fund / Benchmark Total returns(%)
Worldwide Healthcare (Ordinary Share) Price 86.90%
Worldwide Healthcare (Ordinary Share) NAV 98.20%
FTSE World 40.20%
Total Returns on £1000

Discount / Premium Movement

Discount / Premium Movement

Shares

Share Type Yesterday's
Closing Price
Discount / Premium Diluted NAV Gearing Dividend
Est Last
Ordinary Share 2056.0 -8.7% 2251.00 2228.00
26 Jul
112% 0.80%

Discrete performance % over

Fund / BenchmarkAug '13
Jul '14
Aug '14
Jul '15
Aug '15
Jul '16
Worldwide Healthcare (Ordinary Share) Price18.6552.313.42
Worldwide Healthcare (Ordinary Share) NAV20.7848.0210.86
FTSE World6.939.0020.30

Discrete performance over

Discrete Performance

Top 10 Holdings

Boston Scientific, Inc. 4.92%
ONO Pharmaceutical Co., Ltd. 4.51%
AbbVie Inc 4.41%
Intuitive Surgical, Inc. 4.10%
Allergan, Inc. 3.79%
Amgen Inc 3.59%
HCA Holdings Inc 3.28%
Bristol-Myers Squibb Company 3.18%
Alexion Pharmaceuticals, Inc. 3.08%
Roche Holding AG 2.67%

Sectors weighting

Pharmaceuticals 95.50%
Net Current Assets 2.50%
Fixed Interest 1.30%
General Equity 0.80%

Regional weighting

North America Region 63.00%
Europe Developed ex-UK 14.00%
Japan 10.00%
Asia exc Japan 5.00%
Other Countries 4.00%
Cash/Cash Equivalent 2.00%
Fixed Interest 1.00%
UK 1.00%
  • Investment trust info:

  • Sector Sector Specialist: Biotechnology/Life Sciences
  • Launch Date 28 Apr 1995
  • Currency GBX
  • Domicile UK
  • Share Price 2069.56
  • Share Type Ordinary Share
  • TIDM WWH
  • ISIN GB0003385308
  • Shares Issued (M) 47
  • Market Capital (£M) 958.57
  • Gross Assets (£M) 1174.29
  • Net Assets (£M) 1052.08
  • TER (%) 0.96
  • Historic Dividend Yield (%) 0.80
  • Last AGM 24 Sep 2015
  • Next AGM 21 Sep 2016
  • Last Annual Report Date 24 Jun 2016
  • Next due Report Date 30 Sep 2016
  • Next due Report Type I/R
  • Objective:

  • To invest worldwide in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector.
  • Management Group(s):

  • Close Finsbury Asset Management Ltd
  • Frostrow Capital LLP
  • OrbiMed Capital LLC
  • OrbiMed Capital LLC
  • Managed by:

  • Samuel. D Isaly Start: 28 Apr 1995
  • Sven Borho Start: 01 Feb 2013
  • Trevor M. Polischuk Start: 31 Mar 2015
  • Management Contract & Fees:

    OrbiMed, the Investment Manager, receives a periodic fee equal to 0.65% p.a. of the Company's net asset value. The Investment Management Agreement may be terminated by either party giving notice of not less than 12 months. Frostrow, the Administrator, receives a periodic fee equal to 0.30% p.a. of the Company's market capitalisation up to £150m, 0.20% p.a. of the market capitalisation in excess of £ 150m and up to £500m, and 0.125% p.a. of the market capitalisation in excess of £500m, plus a fixed amount equal to £ 57,500 p.a.. Dependent on the level of long-term outperformance of the Company, the Investment Manager and the Administrator are entitled to the payment of a performance fee. The performance fee amounts to 16.5% of any outperformance of the NAV over the benchmark index, the Investment Manager receiving 15% and the Administrator receiving 1.5% respectively.